Pediatrix Q2 2026: Adjusted EPS $0.63 Beats Estimates, Full-Year EBITDA Guidance Reaffirmed

summarizeSummary

Pediatrix Medical Group posted Q2 2026 adjusted EPS of $0.63, beating estimates, and reaffirmed its full-year Adjusted EBITDA guidance of $280–$300 million. Revenue rose 4% to $487.8 million, and the company continued aggressive share buybacks.

check_boxKey Events · Earnings and Guidance · MD

• Q2 Adjusted EPS Beats Estimates

  Adjusted EPS of $0.63 exceeded consensus, up from $0.53 a year ago, driven by 4% revenue growth to $487.8 million and improved collections.

• Full-Year EBITDA Guidance Reaffirmed

  Management reiterated its 2026 Adjusted EBITDA outlook of $280–$300 million, indicating confidence in meeting targets despite restructuring costs.

• Aggressive Share Repurchases Continue

  The company bought back $64.2 million of stock in the first half, reducing the weighted average diluted share count by 4% year-over-year to 82.0 million.

• Revenue Growth Driven by Reimbursement Factors

  Same-unit net revenue increased 1.9%, with a 4.0% boost from net reimbursement-related factors, partially offset by a 2.1% decline in patient volumes.

auto_awesomeAnalysis · MD · Industrial Applications And Services

Pediatrix Medical Group reported second-quarter adjusted earnings of $0.63 per share, beating consensus estimates. Revenue grew 4% to $487.8 million, driven by improved collections and favorable payor mix. The company reaffirmed its full-year 2026 Adjusted EBITDA guidance of $280–$300 million, signaling confidence in its operational trajectory despite ongoing restructuring costs and regulatory headwinds. The quarter also saw aggressive share repurchases—$64.2 million in the first half—reducing the share count and boosting per-share metrics. While operating cash flow turned negative due to incentive compensation payments, the balance sheet remains solid with $288.9 million in cash and full availability on a $450 million revolver.